Journals / Retina-Vitreus / 2004 / Cilt: 12 - Sayı: 1

Antioxidant therapy of age related macular degeneration

Yaşa bağlı makula dejenerasyonunda antioksidan tedavinin etkinliği

Pages
26–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conciusion: We found that fhe anfioxidant treatment beneficial in the treatment of age related macular degeneration but study will be confinued and we hope thaf if will be possible fo say more about this topic.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: We invesfigafed fhe clinical effecfiveness of anfioxidant fherapy for age related macular degeneration (AMD) which has unclear aetiology and treafment.
📊
Key Findings & Data:Material and Methods: The results of 316 eyes of 798 patients which had been diagnosed as AMD and accepted to adminisfer antioxidant treatment were compared with the. resulfs of 98 eyes of 61 patients with AMD who didn\'t accept antioxidant treatment used as control group in a randomised controlled prospective study at GMMA Eye clinics between 1993-2001.
💡
Conclusion & Impact:Conciusion: We found that fhe anfioxidant treatment beneficial in the treatment of age related macular degeneration but study will be confinued and we hope thaf if will be possible fo say more about this topic.
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Maküler dejenerasyon · Yaş faktörü · Antioksidanlar

Abstract

Purpose: We invesfigafed fhe clinical effecfiveness of anfioxidant fherapy for age related macular degeneration (AMD) which has unclear aetiology and treafment. Material and Methods: The results of 316 eyes of 798 patients which had been diagnosed as AMD and accepted to adminisfer antioxidant treatment were compared with the. resulfs of 98 eyes of 61 patients with AMD who didn\'t accept antioxidant treatment used as control group in a randomised controlled prospective study at GMMA Eye clinics between 1993-2001. Results: There were statistical differences between the vision values of two groups from the beginning to the end of the study. But we could not find any difference between fwo groups in the SRN development. Conciusion: We found that fhe anfioxidant treatment beneficial in the treatment of age related macular degeneration but study will be confinued and we hope thaf if will be possible fo say more about this topic.

Özet

Amaç: Etyoloisi ve kesin tedavi protokolü yeterince ortaya konamamış bir hastalık olan yaşa bağlı makula dejenerasyonunda (YBMD) son yıllarda sık tartışılan antioksidan tedavinin klinik etkinliğini araştırmak. Gereç ve Yöntem: 7993-2001 yıllan arasında GATA Göz hastalıkları Kliniği Retina Bölümünde Prospektif, randomize, konrollü, tek kör olarak planlanıp yürütülen çalışmanın 1999 yılına kadar ilk dönem sonuçları alınmıştır. YBMD saptanan ve anfioksidan tedavi verilen 198 olguya ait 316 gözün tedavi sonuçları, önerilen tedaviyi kabul etmeyen 61 hastanın 98 gözü ile oluşturulan kontrol grubu ile karşılaştırıldı. Bulgular: Çalışma gurubunda, tedavi sonrası görme en düşük 0.05, en yüksek tam (ortalama 0.74±0.43) olarak tespit edildi. Kontrol gurubunda, sonuç görmeleri en düşük 0.05, en yüksek tam (ortalama 0.57±0.77) seviyesinde bulundu. Her iki grup arasındaki fark istatistiksel anlamlılık gösteriyordu (p=0.02). Başlangıç ve sonuç görmeleri arasındaki görme keskinliği değişimi çalışma gurubunda -(0.01 ±0.11) kontrol gurubunda -(0.21 ±0.27) seviyesindeydi (p=0.01). Sonuç: Subretinal neovasküler membran gelişimi yönünden anlamlı bir fark bulunamamış olsa da, iki grup arasında sonuç görmeleri ve görme değişimleri yönünden anlamlı farklılıklar bulunması, henüz tedavi protokolü kesinleşmemiş olan YBMD için antioksidan tedavi kombinasyonlarının uygun bir destek sağlayabileceğini düşündürmektedir.

🔖

Cite This Article

ERDEM, Ü., BAYRAKTAR, M. Z., UYSAL, Y. (2004). Antioxidant therapy of age related macular degeneration. Retina-Vitreus, Cilt: 12 - Sayı: 1, 26–29. https://ajindex.com/articles/305368

References (12)

  1. Neely, K. A., Bressler, N. M., Bressler, S.B.: Clinical characteristics, epidemiology and natural history of age related macular degeneration. Ophthalmology Clinics of North America 6: 1996; 291-306
  2. Zarbin, M. A. and Schachat, A. R: Laser therapy of macular disease tOphthalmology Clinics Of North America 6: 1996; 329-345
  3. Hampton, G.R. and Nelsen, R T.: Age Related Macular Degeneration. Laser Ttreatment of AMD 191-229 Raven Press.Newyork 1992
  4. Hyman,L: Age Related Macular Degeneration: Epidemiology of AMD. Raven Press. 1992; 1 -31
  5. Newsome,D.A.: Medical Treatment of Macular Diseases Ophthalmology Clinics of North America, 6: 1996; 307-313 6. Bayraktar Z., Erdem Ü., Uysal Y. ve ark.: AMD olgularında antioksidan tedavi çalışması Türk oftalmoloji derneği XXIX. Ulusal Kongresi Bülteni. Antalya, 1995; 43
  6. Lee, B.C. and Sternberg, R: Phototoxicity of the macula. Ophthalmology Clinics of North America 6: 1996; 231-232
  7. Newsome, D.A., Swartz, M. and Leone, N.C.: Oral zinc and Macular Dejeneration. Arch. Ophthalmology 106: 1988; 192
  8. Himan,L.He.O. and Grimson, R: Rise factors for age related maculopathy. Invest. Ophthalmol. Vis. Sei. 1992; 33.801
  9. Eye Diseases Control Study: Group: Rise factors for neovascular age-related macular degeneration. Arch. Ophthalmol. 1992; 110:1701
  10. Age-Related Eye Disease Study Research Group: Risk factors associated with age-related macular degeneration. A case control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 107: 2000; 2224-2232
  11. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no
  12. Arch Ophthalmol 119: 2001; 1417-1436.